This is a phase I dose escalation study to identify the best dose and side effects of
modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed
by Precigen, Inc) in treating patients with ovarian, fallopian tube, or primary peritoneal
cancer that has spread to other places in the body, that has come back, and is resistant to
platinum chemotherapy. Autologous CAR T cells are modified immune cells that have been
engineered in the laboratory to specifically target a protein found on tumor cells and kill
- Diagnosed with recurrent, advanced, platinum resistant ovarian, fallopian tube, and
primary peritoneal cancer that have progressed after receiving standard of care
therapies or are not eligible to receive available therapies with known clinical
benefit will be eligible for the study. Patients must have measurable disease that can
be accurately measured in at least one dimension as >= 1.0 cm or > 1.5 cm lymph node
with computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI)
- Platinum resistant is defined as progression of disease within six months of
- Patients with BRCA mutations who have completed standard therapies (including
PARP inhibitors) are allowed on this study.
- Patients must be capable of understanding and providing a written informed consent.
- Patients must be of any race or ethnicity.
- Patients at least 14 days from previous cytotoxic chemotherapy.
- Laboratory values must indicate adequate organ function
- Patients must be at least 28 days post systemic steroids prior to enrollment.
- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score
of =< 2.
- Patients must have recovered from major infections and/or surgical procedures, and in
the opinion of the investigator, not have any significant active concurrent medical
illnesses precluding protocol treatment.
- Negative serum pregnancy test for women of childbearing potential. Women of
childbearing potential are those who have not been surgically sterilized, are < 60
years old, or have had menses within the past 12 months.
- Women of childbearing potential must be willing to use 2 methods of contraception
before, during, and at least 4 months after the PRGN-3005 cell infusion.
- Patients with any of the following cardiac conditions:
- Symptomatic restrictive cardiomyopathy
- Unstable angina or symptomatic coronary artery disease within 4 months prior to
- New York Heart Association functional class III-IV heart failure on active
- Symptomatic pericardial effusion
- Congestive heart failure
- Clinically significant hypotension.
- Patients with CA 125 =< ULN during screening.
- Patients with history of human immunodeficiency virus (HIV), West Nile, Zika, or
active hepatitis B or C infections.
- Patients with severe, symptomatic ascites requiring diuretics, regular paracentesis,
or other invasive interventions.
- Patients within 28 days of receiving another investigational agent.
- Patients with pulmonary hypertension, pulmonary fibrosis, or restrictive lung disease,
patients with baseline oxygen saturation on room air < 92%, forced expiratory volume
in 1 second (FEV1) =< 50%, or diffusion capacity of the lung for carbon monoxide
(DLco) (corrected) of < 40% will be excluded.
- Women who are pregnant or breast feeding.
- Patients with second malignancy within the last 5 years excluding basal carcinoma of
the skin, squamous carcinoma of the skin, or in situ cervical dysplasia that has
undergone curative therapy.
- Patients with an active autoimmune disease requiring immunosuppressive therapy or
uncontrolled with treatment.
- Patients who are simultaneously enrolled in any other treatment study.
- Clinical or radiological evidence of acute bowel obstruction within 30 days of
- Patients with known or treated brain metastases.
- Patients with an active seizure disorder.
- Any female patient who does not meet at least one of the following criteria will be
considered to have reproductive potential:
- Post-menopausal for at least 12 consecutive months (i.e., no menses), or
- Undergone a sterilization procedure (hysterectomy, salpingectomy, or bilateral
oophorectomy; tubal ligation is not considered a sterilization procedure).
Pregnancy test for females of reproductive potential must be negative within 14
days before leukapheresis.